Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates-Reference-Cited by-同舟云学术

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates

Published:2017-09-15 Issue:19 Volume:45 Page:10969-10977
ISSN:0305-1048
Container-title:Nucleic Acids Research
language:en
Short-container-title:

Author:

Nair Jayaprakash K.,Attarwala Husain,Sehgal Alfica,Wang Qianfan,Aluri Krishna,Zhang Xuemei,Gao Minggeng,Liu Ju,Indrakanti Ramesh,Schofield Sally,Kretschmer Philip,Brown Christopher R.,Gupta Swati,Willoughby Jennifer L.S.,Boshar Julie A.,Jadhav Vasant,Charisse Klaus,Zimmermann Tracy,Fitzgerald Kevin,Manoharan Muthiah,Rajeev Kallanthottathil G.,Akinc Akin,Hutabarat Renta,Maier Martin A.

Publisher

Oxford University Press (OUP)

Subject

Genetics

Link

http://academic.oup.com/nar/article-pdf/45/19/10969/22934677/gkx818.pdf

Reference31 articles.

1. A highly durable RNAi therapeutic inhibitor of PCSK9;N. Engl. J. Med.,2017

2. Clinical proof of concept for a novel hepatocyte-targeting GalNAc–siRNA conjugate;Mol. Ther.,2017

3. Knocking down disease: a progress report on siRNA therapeutics;Nat. Rev. Genet.,2015

4. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing;J. Am. Chem. Soc.,2014

5. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo;J. Biol. Chem.,2001

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of selective and non-selective C9ORF72 targeting in vivo active siRNAs;Molecular Therapy - Nucleic Acids;2024-09

2. Whole-Body Physiologically-Based Pharmacokinetic Modeling of GalNAc conjugated siRNAs;2024-08-06

3. Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment;Nucleic Acid Therapeutics;2024-08-01

4. Enhancing siRNA efficacy in vivo with extended nucleic acid backbones;Nature Biotechnology;2024-08-01

5. Precision targeting in oncology: The future of conjugated drugs;Biomedicine & Pharmacotherapy;2024-08